

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C12N 15/12, C07K 14/705, 16/28, A61K 38/16, 48/00, C12Q 1/68, G01N 33/68, C12N 15/63, 5/10</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/42580</b> <b>(43) International Publication Date:</b> 26 August 1999 (26.08.99)									
<b>(21) International Application Number:</b> PCT/US99/02904 <b>(22) International Filing Date:</b> 10 February 1999 (10.02.99)  <b>(30) Priority Data:</b> <table border="0"><tr><td>60/075,306</td><td>20 February 1998 (20.02.98)</td><td>US</td></tr><tr><td>9817907.0</td><td>17 August 1998 (17.08.98)</td><td>GB</td></tr><tr><td>09/183,253</td><td>30 October 1998 (30.10.98)</td><td>US</td></tr></table> <b>(71) Applicants:</b> SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). SMITHKLINE BEECHAM PLC [GB/GB]; Three New Horizons Court, Great West Road, Brentford, Middlesex TW8 9EP (GB).  <b>(72) Inventors:</b> VAWTER, Lisa; 1145 North Chester Road, West Chester, PA 19380 (US). STAMMERS, Melanie; 33 Fox Road, Balsham, Cambridgeshire CB1 6EZ (GB).  <b>(74) Agents:</b> ANDERSEN, Robert, L. et al.; Ratner & Prestia, Suite 301, One Westlakes (Berwyn), P.O. Box 980, Valley Forge, PA 19482-0980 (US).		60/075,306	20 February 1998 (20.02.98)	US	9817907.0	17 August 1998 (17.08.98)	GB	09/183,253	30 October 1998 (30.10.98)	US	<b>(81) Designated States:</b> JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
60/075,306	20 February 1998 (20.02.98)	US									
9817907.0	17 August 1998 (17.08.98)	GB									
09/183,253	30 October 1998 (30.10.98)	US									
<b>(54) Title:</b> GABA RECEPTORS AND THEIR USES  <b>(57) Abstract</b>  GABA BP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing GABA BP polypeptides and polynucleotides in therapy, and diagnostic assays for such.											

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## GABA RECEPTORS AND THEIR USES

### Field of the Invention

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and /or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

### Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces 'functional genomics', that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superceding earlier approaches based on 'positional cloning'. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterize further genes and their related polypeptides/proteins, as targets for drug discovery.

It is well established that many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers, e.g., cAMP (Lefkowitz, Nature, 1991, 351:353-354). Herein these proteins are referred to as proteins participating in pathways with G-proteins or PPG proteins. Some examples of these proteins include the GPC receptors, such as those for adrenergic agents and dopamine (Kobilka, B.K., et al., Proc. Natl Acad. Sci., USA, 1987, 84:46-50; Kobilka, B.K., et al., Science, 1987, 238:650-656; Bunzow, J.R., et al., Nature, 1988, 336:783-787), G-proteins themselves, effector proteins, e.g., phospholipase C, adenylyl cyclase, and phosphodiesterase, and actuator proteins, e.g., protein kinase A and protein kinase C (Simon, M.I., et al., Science, 1991, 252:802-8).

- 2 -

For example, in one form of signal transduction, the effect of hormone binding is activation of the enzyme, adenylate cyclase, inside the cell. Enzyme activation by hormones is dependent on the presence of the nucleotide GTP. GTP also influences hormone binding. A G-protein connects the hormone receptor to adenylate cyclase. G-protein was shown to  
5 exchange GTP for bound GDP when activated by a hormone receptor. The GTP-carrying form then binds to activated adenylate cyclase. Hydrolysis of GTP to GDP, catalyzed by the G-protein itself, returns the G-protein to its basal, inactive form. Thus, the G-protein serves a dual role, as an intermediate that relays the signal from receptor to effector, and as a clock that controls the duration of the signal.

10 The membrane protein gene superfamily of G-protein coupled receptors has been characterized as having seven putative transmembrane domains. The domains are believed to represent transmembrane  $\alpha$ -helices connected by extracellular or cytoplasmic loops. G-protein coupled receptors include a wide range of biologically active receptors, such as hormone, viral, growth factor and neuroreceptors.

15 G-protein coupled receptors (otherwise known as 7TM receptors) have been characterized as including these seven conserved hydrophobic stretches of about 20 to 30 amino acids, connecting at least eight divergent hydrophilic loops. The G-protein family of coupled receptors includes dopamine receptors which bind to neuroleptic drugs used for treating psychotic and neurological disorders. Other examples of members of this family  
20 include, but are not limited to, calcitonin, adrenergic, endothelin, cAMP, adenosine, muscarinic, acetylcholine, serotonin, histamine, thrombin, kinin, follicle stimulating hormone, opsins, endothelial differentiation gene-1, rhodopsins, odorant, and cytomegalovirus receptors.

Most G-protein coupled receptors have single conserved cysteine residues in each of  
25 the first two extracellular loops which form disulfide bonds that are believed to stabilize functional protein structure. The 7 transmembrane regions are designated as TM1, TM2, TM3, TM4, TM5, TM6, and TM7. TM3 has been implicated in signal transduction.

Phosphorylation and lipidation (palmitoylation or farnesylation) of cysteine residues can influence signal transduction of some G-protein coupled receptors. Most G-protein  
30 coupled receptors contain potential phosphorylation sites within the third cytoplasmic loop

- 3 -

and/or the carboxy terminus. For several G-protein coupled receptors, such as the b-adrenoreceptor, phosphorylation by protein kinase A and/or specific receptor kinases mediates receptor desensitization.

For some receptors, the ligand binding sites of G-protein coupled receptors are believed to comprise hydrophilic sockets formed by several G-protein coupled receptor transmembrane domains, said socket being surrounded by hydrophobic residues of the G-protein coupled receptors. The hydrophilic side of each G-protein coupled receptor transmembrane helix is postulated to face inward and form polar ligand binding site. TM3 has been implicated in several G-protein coupled receptors as having a ligand binding site, such as the TM3 aspartate residue. TM5 serines, a TM6 asparagine and TM6 or TM7 phenylalanines or tyrosines are also implicated in ligand binding.

G-protein coupled receptors can be intracellularly coupled by heterotrimeric G-proteins to various intracellular enzymes, ion channels and transporters (see, Johnson et al., Endoc. Rev., 1989, 10:317-331). Different G-protein  $\alpha$ -subunits preferentially stimulate particular effectors to modulate various biological functions in a cell. Phosphorylation of cytoplasmic residues of G-protein coupled receptors have been identified as an important mechanism for the regulation of G-protein coupling of some G-protein coupled receptors. G-protein coupled receptors are found in numerous sites within a mammalian host.

Over the past 15 years, nearly 350 therapeutic agents targeting 7 transmembrane (7 TM) receptors have been successfully introduced onto the market.

### Summary of the Invention

The present invention relates to GABA BP, in particular GABA BP polypeptides and GABA BP polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and

- 4 -

neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome, hereinafter referred to as "the Diseases", amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with GABA BP imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate GABA BP activity or levels.

#### **Description of the Invention**

In a first aspect, the present invention relates to GABA BP polypeptides. Such peptides include isolated polypeptides comprising an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

Further peptides of the present invention include isolated polypeptides in which the amino acid sequence has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2.

Further peptides of the present invention include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1.

Polypeptides of the present invention are believed to be members of the G protein-coupled receptor family of polypeptides. They are therefore of interest because G protein-coupled receptors are the basis of much of cell-to-cell communication in human bodies. As such, they have been the basis of action of more pharmaceutical drugs than any other gene family. These properties are hereinafter referred to as "GABA BP activity" or "GABA BP polypeptide activity" or "biological activity of GABA BP". Also included amongst these

- 5 -

activities are antigenic and immunogenic activities of said GABA BP polypeptides, in particular the antigenic and immunogenic activities of the polypeptide of SEQ ID NO:2. Preferably, a polypeptide of the present invention exhibits at least one biological activity of GABA BP.

5           The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

10           The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or  
15           aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

          Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a  
20           combination of these methods. Means for preparing such polypeptides are well understood in the art.

          In a further aspect, the present invention relates to GABA BP polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 70 % identity, preferably at least 80 % identity, more  
25           preferably at least 90 % identity, yet more preferably at least 95 % identity, to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2. In this regard, polypeptides which have at least 97 % identity are highly preferred, whilst those with at least 98-99 % identity are more highly preferred, and those with at least 99 % identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide  
30           sequence contained in SEQ ID NO:1 encoding the polypeptide of SEQ ID NO:2.

- 6 -

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 70 % identity, preferably at least 80 % identity, more preferably at least 90 % identity, yet more preferably at least 95 % identity, to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, over the entire coding region. In this regard, polynucleotides which have at least 97 % identity are highly preferred, whilst those with at least 98-99 % identity are more highly preferred, and those with at least 99 % identity are most highly preferred.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence which has at least 70 % identity, preferably at least 80 % identity, more preferably at least 90 % identity, yet more preferably at least 95 % identity, to SEQ ID NO:1 over the entire length of SEQ ID NO:1. In this regard, polynucleotides which have at least 97 % identity are highly preferred, whilst those with at least 98-99 % identity are more highly preferred, and those with at least 99 % identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 as well as the polynucleotide of SEQ ID NO:1.

The invention also provides polynucleotides which are complementary to all the above described polynucleotides.

The nucleotide sequence of SEQ ID NO:1 shows homology with Genbank: Y11044 | HSGTHLA1 H.sapiens mRNA for hypothetical protein within HLA class

I. The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 322 to 1279) encoding a polypeptide of 319 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of the SEQ ID NO:2 is structurally related to other proteins of the a G protein-coupled receptor family, having homology and/or structural similarity with GenBank: Nonred:gil929419 (Kaupmann K, et al., Nature 1997 March 20; 386(6622): 239-246).



- 7 -

Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one GABA BP activity.

5           The present invention also relates to partial or other polynucleotide and polypeptide sequences which were first identified prior to the determination of the corresponding full length sequences of SEQ ID NO:1 and SEQ ID NO:2.

Accordingly, in a further aspect, the present invention provides for an isolated polynucleotide which:

10       (a) comprises a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;

15       (b) has a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to SEQ ID NO:3 over the entire length of SEQ ID NO:3;

(c) the polynucleotide of SEQ ID NO:3; or

20       (d) a nucleotide sequence encoding a polypeptide which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4, over the entire length of SEQ ID NO:4;

as well as the polynucleotide of SEQ ID NO:3.

The present invention further provides for a polypeptide which:

25       (a) comprises an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4;

- 8 -

(b) has an amino acid sequence which is at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4;

5 (c) comprises the amino acid of SEQ ID NO:4; and

(d) is the polypeptide of SEQ ID NO:4;

as well as polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

The nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded  
10 thereby are derived from EST (Expressed Sequence Tag) sequences. It is recognized by those skilled in the art that there will inevitably be some nucleotide sequence reading errors in EST sequences (see Adams, M.D. *et al.*, Nature 377 (supp) 3, 1995). Accordingly, the nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded therefrom are therefore subject to the same inherent limitations in sequence accuracy.  
15 Furthermore, the peptide sequence encoded by SEQ ID NO:3 comprises a region of identity or close homology and/or close structural similarity (for example a conservative amino acid difference) with the closest homologous or structurally similar protein.

Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human  
20 hippocampus, using the expressed sequence tag (EST) analysis (Adams, M.D., *et al.* Science (1991) 252:1651-1656; Adams, M.D. *et al.*, Nature, (1992) 355:632-634; Adams, M.D., *et al.*, Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

25 When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide

- 9 -

portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Further embodiments of the present invention include polynucleotides encoding polypeptide variants which comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 5 to 10, 1 to 5, 1 to 3, 1 to 2 or 1, amino acid residues are substituted, deleted or added, in any combination.

Polynucleotides which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO:1, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1. Typically these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% identical, most preferably 95% identical to that of the referent. The probes or primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50%

- 10 -

formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C.

Thus the present invention also includes polynucleotides obtainable by screening an

5 appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is short at the 5' end of the cDNA. This is a consequence of reverse transcriptase, an enzyme with inherently low  
10 'processivity' (a measure of the ability of the enzyme to remain attached to the template during the polymerization reaction), failing to complete a DNA copy of the mRNA template during 1st strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method  
15 of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence  
20 ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the 'missing' 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that  
25 anneals further 5' in the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

- 11 -

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems which comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., *Basic Methods in Molecular Biology* (1986) and Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any

- 12 -

system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (supra). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterized by the polynucleotide of SEQ ID NO:1 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

- 13 -

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled GABA BP nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (e.g., Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising GABA BP nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M. Chee *et al.*, Science, Vol. 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the GABA BP gene by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

- 14 -

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

(a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment thereof ;

5 (b) a nucleotide sequence complementary to that of (a);

(c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof; or

(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.

10 It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary  
15 retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles de la Tourette's, amongst others.

20 The nucleotide sequences of the present invention are also valuable for chromosome localization. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise  
25 chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University-Welch Medical Library). The relationship between genes and diseases that have been mapped to the



- 15 -

same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

The gene of the present invention maps to human chromosome 9q22.

The nucleotide sequences of the present invention are also valuable for tissue localization. Such techniques allow the determination of expression patterns of the human GABA BP polypeptides in tissues by detection of the mRNAs that encode them. These techniques include in situ hybridization techniques and nucleotide amplification techniques, for example PCR. Such techniques are well known in the art. Results from these studies provide an indication of the normal functions of the polypeptides in the organism. In addition, comparative studies of the normal expression pattern of human GABA BP mRNAs with that of mRNAs encoded by a human GABA BP gene provide valuable insights into the role of mutant human GABA BP polypeptides, or that of inappropriate expression of normal human GABA BP polypeptides, in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell

- 16 -

hybridoma technique (Kozbor *et al.*, Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, Monoclonal Antibodies and Cancer Therapy, 77-96, Alan R. Liss, Inc., 1985).

5 Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

10 Antibodies against polypeptides of the present invention may also be employed to treat the Diseases, amongst others.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the  
15 constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion  
20 proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

25 Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response to protect said animal from the Diseases hereinbefore mentioned, amongst others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering a polypeptide of the present invention *via* a vector directing

- 17 -

expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases.

A further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a polypeptide of the present invention wherein the composition comprises a polypeptide or polynucleotide of the present invention. The vaccine formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention are responsible for one or more biological functions, including one or more disease states, in particular the Diseases hereinbefore mentioned. It is therefore desirable to devise screening methods to identify compounds which stimulate or which inhibit the function of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate or which inhibit the function of the polypeptide. In general, agonists or antagonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists, antagonists or inhibitors so-identified may be natural or modified substrates,

- 18 -

ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring GABA BP activity in the mixture, and comparing the GABA BP activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and GABA BP polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

One screening technique includes the use of cells which express receptor of this invention (for example, transfected CHO cells) in a system which measures extracellular pH or intracellular calcium changes caused by receptor activation. In this technique, compounds may be contacted with cells expressing the receptor polypeptide of the present invention. A second messenger response, e.g., signal transduction, pH changes, or changes in calcium level, is then measured to determine whether the potential compound activates or inhibits the receptor.

- 19 -

Another method involves screening for receptor inhibitors by determining inhibition or stimulation of receptor-mediated cAMP and/or adenylate cyclase accumulation. Such a method involves transfecting a eukaryotic cell with the receptor of this invention to express the receptor on the cell surface. The cell is then exposed to potential antagonists in the presence of the receptor of this invention. The amount of cAMP accumulation is then measured. If the potential antagonist binds the receptor, and thus inhibits receptor binding, the levels of receptor-mediated cAMP, or adenylate cyclase, activity will be reduced or increased.

Another method for detecting agonists or antagonists for the receptor of the present invention is the yeast based technology as described in U.S. Patent 5,482,835.

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance,  $^{125}\text{I}$ ), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

- 20 -

Examples of potential polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which decrease or enhance the production of such polypeptides, which comprises:

- (a) a polypeptide of the present invention;
  - (b) a recombinant cell expressing a polypeptide of the present invention;
  - (c) a cell membrane expressing a polypeptide of the present invention; or
  - (d) antibody to a polypeptide of the present invention;
- which polypeptide is preferably that of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist, antagonist or inhibitor of the polypeptide, by:

- (a) determining in the first instance the three-dimensional structure of the polypeptide;
- (b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist, antagonist or inhibitor;
- (c) synthesizing candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and
- (d) testing whether the candidate compounds are indeed agonists, antagonists or inhibitors.

It will be further appreciated that this will normally be an iterative process.

- 21 -

In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; 5 hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; stroke; ulcers; asthma; allergies; benign prostatic hypertrophy; migraine; vomiting; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, depression, delirium, dementia, and severe mental retardation; and dyskinesias, such as Huntington's disease or Gilles de la Tourette's syndrome., related to either an excess of, or an under- 10 expression of, GABA BP polypeptide activity.

If the activity of the polypeptide is in excess, several approaches are available. One approach comprises administering to a subject in need thereof an inhibitor compound (antagonist) as hereinabove described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function of the polypeptide, such as, 15 for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the GABA BP 20 polypeptide.

In still another approach, expression of the gene encoding endogenous GABA BP polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or externally administered (see, for example, O'Connor, J Neurochem (1991) 56:560 in 25 Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Alternatively, oligonucleotides which form triple helices ("triplexes") with the gene can be supplied (see, for example, Lee *et al.*, Nucleic Acids Res (1979) 6:3073; Cooney *et al.*, Science (1988) 241:456; Dervan *et al.*, Science (1991) 251:1360). These oligomers can be administered *per se* or the relevant oligomers can be expressed *in* 30 *vivo*. Synthetic antisense or triplex oligonucleotides may comprise modified bases or

- 22 -

modified backbones. Examples of the latter include methylphosphonate, phosphorothioate or peptide nucleic acid backbones. Such backbones are incorporated in the antisense or triplex oligonucleotide in order to provide protection from degradation by nucleases and are well known in the art. Antisense and triplex molecules synthesized with these or other modified backbones also form part of the present invention.

In addition, expression of the human GABA BP polypeptide may be prevented by using ribozymes specific to the human GABA BP mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, et al., Curr. Opin. Struct. Biol (1996) 6(4), 527-33.) Synthetic ribozymes can be designed to specifically cleave human GABA BP mRNAs at selected positions thereby preventing translation of the human GABA BP mRNAs into functional polypeptide. Ribozymes may be synthesized with a natural ribose phosphate backbone and natural bases, as normally found in RNA molecules. Alternatively the ribozymes may be synthesized with non-natural backbones to provide protection from ribonuclease degradation, for example, 2'-O-methyl RNA, and may contain modified bases.

For treating abnormal conditions related to an under-expression of GABA BP and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition.

Alternatively, gene therapy may be employed to effect the endogenous production of GABA BP by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A



- 23 -

P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide, such as the soluble form of a polypeptide of the present invention, agonist/antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100  $\mu\text{g/kg}$  of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection.

- 24 -

Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

Polynucleotide and polypeptide sequences form a valuable information resource with which to identify further sequences of similar homology. This is most easily facilitated by storing the sequence in a computer readable medium and then using the stored data to search a sequence database using well known searching tools, such as those in the GCG and Lasergene software packages. Accordingly, in a further aspect, the present invention provides for a computer readable medium having stored thereon a polynucleotide comprising the sequence of SEQ ID NO:1 and/or a polypeptide sequence encoded thereby.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA,

- 25 -

DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition,

5 "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus,

10 "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino

15 acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids.

"Polypeptides" include amino acid sequences modified either by natural processes, such

20 as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of

25 modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications

30 include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a

- 26 -

nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62).

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

- 27 -

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)

Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad. Sci. USA.* 89:10915-10919 (1992)

Gap Penalty: 12

Gap Length Penalty: 4

- 28 -

A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

- 5 1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These  
10 are the default parameters for nucleic acid comparisons.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one  
15 nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined  
20 by multiplying the total number of nucleotides in SEQ ID NO:1 by the numerical percent of the respective percent identity(divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides  
25 in SEQ ID NO:1, and  $y$  is, for instance, 0.70 for 70 %, 0.80 for 80 %, 0.85 for 85 %, 0.90 for 90 %, 0.95 for 95 %, etc., and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense,

- 29 -

missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \cdot y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:2, and  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described.

Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species.

- 30 -

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region  
5 as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

All publications, including but not limited to patents and patent applications, cited  
10 in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.



- 31 -

## SEQUENCE LISTING FREE TEXT

## SEQUENCE INFORMATION

## SEQ ID NO:1

ATGCCACCGCCGCGCGCCTGCTACTGCTACTGCTGCTGCCGCTGCTGCTGCCTCTGGCGCCCGGGG  
5 CTGGGGCTGGGCGGGGCGCCCCCGGCCGCCAGCAGCCCGCGCTCTCCATCATGGGCCTCATGC  
CGCTCACCAAGGAGGTGGCCAAGGGCAGCATCGGGCGCGGTGTGCTCCCCGCGTGGAATGGCCATCGAG  
CAGATCCGCAACGAGTCACTCCTGCGCCCCCTACTTCCTCGACCTGCGGCTCTATGACACGGAGTGCGACAA  
CGAAAAGGGTTGAAAGCCTTCTACGATGCAATAAAATACGGGCCGAACCACTTGATGGTGTGTTGGAGGCG  
TCTGTCCATCCGTACATCCATCATTGCAGAGTCCCTCCAAGGCTGGAATCTGGTGCAGCTTCTTTTGCT  
10 GCAACCACGCCTGTTCTAGCCGATAAGAAAAAATACCTTATTTCTTTTCGGACCGTCCCATCAGACAATGC  
GGTGAATCCAGCCATTCTGAAGTTGCTCAAGCACTACCAGTGAAGCGCGTGGGCAGCTGACGCAAGACG  
TTCAGAGGTTCTCTGAGGTGCGGAATGACCTGACTGGAGTTCTGTATGGCGAGGACATTGAGATTTGAGAC  
ACCGAGAGCTTCTCCAACGATCCCTGTACCAGTGTCAAAAAGCTGAAGGGGAATGATGTGCGGATCATCCT  
TGGCCAGTTTGACCAGAATATGGCAGCAAAAGTGTCTGTGTACTCCACAGCAGTATGAGAGAGAGTACA  
15 ACAACAAGCGGTGAGGCGTGGGGCCAGCAAGTTCCACGGGTACGCCTACGATGGCATCTGGGTCATCGCC  
AAGACACTGCAGAGGGCCATGGAGACACTGCATGCCAGCAGCCGGCACCAGCGGATCCAGGACTTCAACTA  
CACGGACCACACGCTGGGCAGGATCATCCTCAATGCCATGAACGAGACCAACTTCTTCGGGGTCACGGGTC  
AAGTTGTATTCCGGAATGGGGAGAGAATGGGGACCATTAAATTTACTCAATTTCAAGACAGCAGGGAGGTG  
AAGGTGGGAGAGTACAACGCTGTGGCCGACACACTGGAGATCATCAATGACACCATCAGGTTCCAAGGATC  
20 CGAACCACCAAAAGACAAGACCATCATCCTGGAGCAGCTGCGGAAGATCTCCCTACCTCTCTACAGCATCC  
TCTCTGCCCTCACCATCCTCGGGATGATCATGGCCAGTGCTTTTCTCTTCTTCAACATCAAGAACCAGGAAT  
CAGAAGCTCATAAAGATGTCGAGTCCATACATGAACAACCTTATCATCCTTGGAGGGATGCTCTCCTATGC  
TTCCATATTTCTCTTTGGCCTTGATGGATCCTTTGTCTCTGAAAAGACCTTTGAAACACTTTGCACCGTCA  
GGACCTGGATTCTCACCGTGGGCTACACGACCGCTTTTGGGGCCATGTTTGAAAGACCTGGAGAGTCCAC  
25 GCCATCTTCAAAAATGTGAAAATGAAGAAGAAGATCATCAAGGACCAGAACTGCTTGTGATCGTGGGGGG  
CATGCTGCTGATCGACCTGTGTATCCTGATCTGCTGGCAGGCTGTGGACCCCTGCGAAGGACAGTGGAGA  
AGTACAGCATGGAGCCGGACCCAGCAGGACGGGATATCTCCATCCGCCCTCTCCTGGAGCACTGTGAGAAC  
ACCCATATGACCATCTGGCTTGGCATCGTCTATGCCTACAAGGGACTTCTCATGTTGTTTCGGTTGTTTCTT  
AGCTTGGGAGACCCGCAACGTGAGCATCCCTGCACCTAACGACAGCAAGTACATCGGGATGAGTGTCTACA  
30 ACGTGGGGATCATGTGCATCATCGGGGCCGCTGTCTCCTTCTGACCCGGGACCAGCCCAATGTGCAGTTC  
TGCATCGTGCTCTGGTTCATCATCTTCTGCAGCACCATCACCCTCTGCCTGGTATTCTGTGCCGAAGCTCAT  
CACCCTGAGAACAAACCCAGATGCAGCAACGCAGAACAGGCGATTCCAGTTCACCTCAGAATCAGAAGAAAG  
AAGATTCTAAAACGTCCACCTCGGTCAACAGTGTGAACCAAGCCAGCACATCCCGCCTGGAGGGCCTACAG  
TCAGAAAACCATCGCCTGCGAATGAAGATCACAGAGCTGGATAAAGACTTGAAGAGGTACCATGCAGCT  
35 GCAGGACACACCAGAAAAGACCACCTACATTAAACAGAACCCTACCAAGAGCTCAATGACATCCTCAACC  
TGGGAAACTTCACTGAGAGCACAGATGGAGGAAAGGCCATTTTAAAAAATCACCTTGATCAAAATCCCCAG

- 32 -

CTACAGTGGAAACACAACAGAGCCCTCTCGAACATGCAAAGATCCTATAGAAGATATAAACTCTCCAGAACA  
CATCCAGCGTCGGCTGTCCCTCCAGCTCCCCATCCTCCACCACGCCTACCTCCCATCCATCGGAGGCGTGG  
ACGCCAGCTGTGTGACGCCCTGCGTCAGCCCCACCGCCAGCCCCCGCCACAGACATGTGCCACCCTCCTTC  
CGAGTCATGGTCTCGGGCCTGTAAGGTTGGGAGGCCTGGGCCCGGGCCTCCCCCGTGACAGAACCACACT  
5 GGGCAGAGGGGTCTGCTGCAGAAACACTGTGCGCTCTGGCTGCGGAGAAGCTGGGCACCATGGCTGGCCTC  
TCAGGACCACTCGGATGGCACTCAGGTGGACAGGACGGGGCAGGGGGAGACTTGGCACCTGACCTCGAGCC  
TTATTTGTGAAGTCCTTATTTCTTCACAAAGAAGAGGAACGGAAATGGGACGTCTTCCTTAACATCTGCAA  
ACAAGGAGGCGCTGGGATATCAAACCTTGCAAAAAAAAAAAAAAAAAAAAA

10

## SEQ ID NO:2

MPPPPARLLLLLLLLPLLLPLAPGAWGWARGAPRPPSSPPLSIMGLMPLTKEVAKSIGRGLPAVELAIE  
QIRNESLLRPYFLDLRLYDTECDNAKGLKAFYDAIKYGNHLMVFGGVCPSVTSIIAESLQGNLVQLSFA  
ATTPVLADKKKYPYFFRTVPSDNAVNPAAILKLLKHYQWKRVGTLTQDVQRFSEVRNDLTGVLYGEDIEISD  
15 TESFSNDPCTSVKKLKGNDVRIILGQFDQNMAAKVFCCTPQQYEREYNNKRSVGPSKFHGYAYDGIWVIA  
KTLQRAMETLHASSRHQRIQDFNYTDHTLGRIILNAMNETNFFGVGTQVVFRNGERMGTIKFTQFQDSREV  
KVGEYNAVADTLEIINDTIRFQGSEPPKDKTIILEQLRKISLPLYSILSALTILGMIMASAFLLFNINRNR  
QKLIKMSSPYMNLIILGGMLSASIFLFLDGSFVSEKTFETLCTVRTWILTVGYTTAFGAMFAKTWRVH  
AIFKNVMMKKKI IKDQKLLVIVGGMLLIDLCLICWQAVDPLRRTVEKYSMEPDPAGRDISIRPLLEHCEN  
20 THMTIWLGI VYAYKGLMLFGCFLAWETRNV SIPALNDSKYIGMSVYVNGIMCIIGA AVSFLTRDQPNVQF  
CIVALVII F CSTITLCLVFV PKLITLR TNPD AATQNR RFQFTQ NQKKEDSKTSTSVTSVNQASTSRLEGLQ  
SENHRLRMKITELDKDLEEV TMLQDTP EKT TYIKQNH YQELNDILNLGNFT ESTDGGKAILKNHLDQNPQ  
LQWNTTEPSRTCKDPIEDINSPEHIQRRLSLQLPILHHAYLPSIGGVDASCVSPCVSPTASPRHRHVPPSF  
RVMVSGL

25

## SEQ ID NO:3

GGCACGAGGATCATTCGGGCTGGTACGAGCCTTCTTGGTGGGAGCAGGTGCACACGGAA  
GCCAACTCATCCCGTGCCTCCGGAAGAATCTGCTTGCTGCCATGGAGGGCTACATTGGC  
30 GTGGATTTGAGCCCCTGAGCTCCAAGCAGATCAAGACCATCTCAGGAAAGACTCCACAG  
CAGTATGAGAGAGAGTACAACAACAAGCGGTCAGGCGTGGGGCCAGCAAGTTCCACGGG  
TACGCCTACGATGGCATCTGGGTCATCGCCAAGACACTGCAGAGGGCCATGGAGACACTG  
CATGCCAGCAGCCGGCACCAGCGGATCCAGGACTTCAACTACACGGACCACACGCTGGGC  
AGGATCATCCTCAATGCCATGAACGAGACCAACTTCTTCGGGGTCACGGGTCAAGTTGTA  
35 TTCCGGAATGGGAGAGAATGGGGACCATTAATTTACTCAATTTCAAGACAGCAGGGAG  
GTGAAGGTGGGAGAGTACAACGCTGTGGCCGACACACTGGAGATCATCAATGACACCATC  
AGGTTCCAAGGATCCGAACCACAAAAGACAAGACCATCATCCTGGAGCAGCTGCGGAAG  
ATCTCCCTACCTCTCTACAGCATCCTCTCTGCCCTCACCATCCTCGGGATGATCATGGCC  
AGTGCTTTTCTCTTCTTCAACATCAAGAACCAGGAATCAGAAGCTCATAAAGATGTGAGT  
40 CCATACATGAACAACCTTATCATCCTTGGAGGGATGCTCTCCTATGCTTCCATATTTCTC

- 33 -

TTTGGCCTTGATGGATCCTTTGTCTCTGAAAAGACCTTTGAAACACTTTGCACCGTCAGG  
ACCTGGATTCTCACCCTGGGCTACACGACCGCTTTTGGGGCCATGTTTGCAAAGACCTGG  
AGAGTCCACGCCATCTTCAAAAATGTGAAAATGAAGAAGAAGATCATCAAGGACCAGAAA  
CTGCTTGTGATCGTGGGGGGCATGCTGCTGATCGACCTGTGTATCCTGATCTGCTGGCAG  
5 GCTGTGGACCCCTGCGAAGGACAGTGGAGAAGTACAGCATGGAGCCGGACCCAGCAGGA  
CGGGATATCTCCATCCGCCCTCTCCTGGAGCACTGTGAGAACACCCATATGACCATCTGG  
CTTGGCATCGTCTATGCCTACAAGGGACTTCTCATGTTGTTTCGGTTGTTTCTTAGCTTGG  
GAGACCCGCAACGTGAGCATCCCCGCACTCAACGACAGCAAGTACATCGGGATGAGTGTC  
10 TACAACGTGGGGATCATCTCGTGCCGAATTCGATATCAAGCTTATCGATACCGTCGAC

## SEQ ID NO:4

RIQDFNYTDHTLGRIILNAMNETNFFGVGTGQVVRNGERMGTIKFTQFQDSREVKVGEYN  
AVADTLEIINDTIRFQGSEPPKDKTIILEQLRKISLPLYSILSALTILGMIMASAFLEFFN  
15 IKNRNQKLIKSSPYMNNLIILGGMLSYASIFLFGLDGSFVSEKTFETLCTVRTWILTVG  
YTTAFGAMFAKTWRVHAIFKNVKMKKKI IKDQKLLVIVGGMLLIDLCLICWQAVDPLRR  
TVEKYSMEPDPAGRDISIRPLLEHCENTHMTIWLGI VYAYKGLLMLFGCFLAWETRNVSI  
PALNDSKYIGMSVYNVGIHSCRIRYQAYRYRR

- 34 -

**What is claimed is:**

## 1. An isolated polypeptide selected from the group consisting of:

(i) an isolated polypeptide comprising an amino acid sequence selected from the group having at least:

5 (a) 70% identity;

(b) 80% identity;

(c) 90% identity; or

(d) 95% identity

10 to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2;

(ii) an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2  
or

(iii) an isolated polypeptide which is the amino acid sequence of SEQ ID NO:2.

## 15 2. An isolated polynucleotide selected from the group consisting of:

(i) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least

(a) 70% identity;

(b) 80% identity;

20 (c) 90% identity; or

(d) 95% identity;

to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2;

(ii) an isolated polynucleotide comprising a nucleotide sequence that has at least:

25 (a) 70% identity

- 35 -

- (b) 80 % identity;
- (c) 90 % identity; or
- (d) 95 % identity;

over its entire length to a nucleotide sequence encoding the polypeptide of SEQ ID NO:2;

(iii) an isolated polynucleotide comprising a nucleotide sequence which has at least:

- (a) 70 % identity;
- (b) 80 % identity;
- (c) 90 % identity; or
- (d) 95 % identity;

to that of SEQ ID NO: 1 over the entire length of SEQ ID NO:1;

(iv) an isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2;

(v) an isolated polynucleotide which is the polynucleotide of SEQ ID NO: 1; or

(vi) an isolated polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof.;

or a nucleotide sequence complementary to said isolated polynucleotide.

3. An antibody immunospecific for the polypeptide of claim 1.

4. A method for the treatment of a subject:

(i) in need of enhanced activity or expression of the polypeptide of claim 1 comprising:

- (a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; and/or

- 36 -

(b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence encoding said polypeptide in a form so as to effect production of said polypeptide activity *in vivo.*; or

(ii) having need to inhibit activity or expression of the polypeptide of claim 1 comprising:

(a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; and/or

(b) administering to the subject a nucleic acid molecule that inhibits the expression of a nucleotide sequence encoding said polypeptide; and/or

(c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate, or receptor.

5. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of the polypeptide of claim 1 in a subject comprising:

(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in the genome of said subject; and/or

(b) analyzing for the presence or amount of said polypeptide expression in a sample derived from said subject.

6. A method for screening to identify compounds which stimulate or which inhibit the function of the polypeptide of claim 1 which comprises a method selected from the group consisting of:

(a) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;

- 37 -

(b) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;

(c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide;

(d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a standard; or

(e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and said polypeptide in cells, using for instance, an ELISA assay.

7. An agonist or an antagonist of the polypeptide of claim 1.

8. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression system is present in a compatible host cell.

9. A process for producing a recombinant host cell comprising transforming or transfecting a cell with the expression system of claim 8 such that the host cell, under appropriate culture conditions, produces a polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2.

10. A recombinant host cell produced by the process of claim 9.

- 38 -

11. A membrane of a recombinant host cell of claim 10 expressing a polypeptide comprising an amino acid sequence having at least 70% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2.

5 12. A process for producing a polypeptide comprising culturing a host cell of claim 10 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.

13. An isolated polynucleotide selected from the group consisting of:

- 10 (a) an isolated polynucleotide comprising a nucleotide sequence which has at least 70%, 80%, 90%, 95%, 97% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;
- (b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:3;
- (c) the polynucleotide of SEQ ID NO:3; or
- (d) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide
- 15 which has at least 70%, 80%, 90%, 95%, 97-99% identity to the amino acid sequence of SEQ ID NO:4, over the entire length of SEQ ID NO:4.

14. A polypeptide selected from the group consisting of:

- (a) a polypeptide which comprises an amino acid sequence which has at least 70%, 80%, 90%, 95%, 97-99% identity to that of SEQ ID NO:4 over the entire length of
- 20 SEQ ID NO:4;
- (b) a polypeptide which has an amino acid sequence which is at least 70%, 80%, 90%, 95%, 97-99% identity to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4;
- (c) a polypeptide which comprises the amino acid of SEQ ID NO:4;
- 25 (d) a polypeptide which is the polypeptide of SEQ ID NO:4; or
- (e) a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.



1/7

## SEQUENCE LISTING

## (1) GENERAL INFORMATION

- (i) APPLICANT: SMITHKLINE BEECHAM CORPORATION  
SMITHKLINE BEECHAM plc
- (ii) TITLE OF THE INVENTION: NOVEL COMPOUNDS
- (iii) NUMBER OF SEQUENCES: 4
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Ratner & Prestia
  - (B) STREET: P.O. Box 980
  - (C) CITY: Valley Forge
  - (D) STATE: PA
  - (E) COUNTRY: USA
  - (F) ZIP: 19482
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette
  - (B) COMPUTER: IBM Compatible
  - (C) OPERATING SYSTEM: DOS
  - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: TO BE ASSIGNED
  - (B) FILING DATE:
  - (C) CLASSIFICATION: UNKNOWN
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: 60/075,306
  - (B) FILING DATE: 20-FEB-1998
  - (A) APPLICATION NUMBER: 9817907.0
  - (B) FILING DATE: 17-AUG-1998
  - (A) APPLICATION NUMBER: 09/183,253
  - (B) FILING DATE: 30-OCT-1998
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Prestia, Paul F
  - (B) REGISTRATION NUMBER: 23,031
  - (C) REFERENCE/DOCKET NUMBER: GP-70395
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: 610-407-0700
  - (B) TELEFAX: 610-407-0700
  - (C) TELEX: 846169

2/7

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2887 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGCCACCGC	CGCCCGCGCG	CCTGCTACTG	CTACTGCTGC	TGCCGCTGCT	GCTGCCTCTG	60
GCGCCCGGGG	CCTGGGGGCTG	GGCGCGGGGC	GCCCCCGGC	CGCCGCCAG	CAGCCCGCCG	120
CTCTCCATCA	TGGGCCTCAT	GCCGCTCACC	AAGGAGGTGG	CCAAGGGCAG	CATCGGGCGC	180
GGTGTGCTCC	CGCCCGTGGG	ACTGGCCATC	GAGCAGATCC	GCAACGAGTC	ACTCCTGCGC	240
CCCTACTTCC	TCGACCTGCG	GCTCTATGAC	ACGGAGTGCG	ACAACGCAAA	AGGGTTGAAA	300
GCCTTCTACG	ATGCAATAAA	ATACGGGCCG	AACCACTTGA	TGGTGTCTTG	AGGCGTCTGT	360
CCATCCGTCA	CATCCATCAT	TGCAGAGTCC	CTCCAAGGCT	GGAATCTGGT	GCAGCTTTCT	420
TTTGTGCAAA	CCACGCCTGT	TCTAGCCGAT	AAGAAAAAAT	ACCCTTATTT	CTTTCGGACC	480
GTCCCATCAG	ACAAATGCGGT	GAATCCAGCC	ATTCTGAAGT	TGCTCAAGCA	CTACCAGTGG	540
AAGCGCGTGG	GCACGCTGAC	GCAAGACGTT	CAGAGGTTCT	CTGAGGTGCG	GAATGACCTG	600
ACTGGAGTTC	TGTATGGCGA	GGACATTGAG	ATTTTCAGACA	CCGAGAGCTT	CTCCAACGAT	660
CCCTGTACCA	GTGTCAAAAA	GCTGAAGGGG	AATGATGTGC	GGATCATCCT	TGGCCAGTTT	720
GACCAGAATA	TGGCAGCAAA	AGTGTCTGT	TGTACTCCAC	AGCAGTATGA	GAGAGAGTAC	780
AACAACAAGC	GGTCAGGCGT	GGGGCCAGC	AAGTTCACG	GGTACGCCTA	CGATGGCATC	840
TGGGTCAATC	CCAAGACACT	GCAGAGGGCC	ATGGAGACAC	TGCATGCCAG	CAGCCGGCAC	900
CAGCGGATCC	AGGACTTCAA	CTACACGGAC	CACACGCTGG	GCAGGATCAT	CCTCAATGCC	960
ATGAACGAGA	CCAACCTCTT	CGGGGTACAG	GGTCAAGTTG	TATTCCGGAA	TGGGGAGAGA	1020
ATGGGGACCA	TTAAATTTAC	TCAATTTCAA	GACAGCAGGG	AGGTGAAGGT	GGGAGAGTAC	1080
AACGCTGTGG	CCGACACACT	GGAGATCATC	AATGACACCA	TCAGGTTCCA	AGGATCCGAA	1140
CCACCAAAAG	ACAAGACCAT	CATCCTGGAG	CAGTGCAGGA	AGATCTCCCT	ACCTCTCTAC	1200
AGCATCCTCT	CTGCCCTCAC	CATCCTCGGG	ATGATCATGG	CCAGTGCTTT	TCTCTTCTTC	1260
AACATCAAGA	ACCGGAATCA	GAAGCTCATA	AAGATGTGCA	GTCCATACAT	GAACAACCTT	1320
ATCATCCTTG	GAGGGATGCT	CTCCTATGCT	TCCATATTTT	TCTTTGGCCT	TGATGGATCC	1380
TTTGTCTCTG	AAAAGACCTT	TGAAACACTT	TGCACCGTCA	GGACCTGGAT	TCTCACCGTG	1440
GGCTACACGA	CCGCTTTTGG	GGCCATGTTT	GCAAAGACCT	GGAGAGTCCA	CGCCATCTTC	1500
AAAAATGTGA	AAATGAAGAA	GAAGATCATC	AAGGACCAGA	AACTGCTTGT	GATCGTGGGG	1560
GGCATGCTGC	TGATCGACCT	GTGTATCCTG	ATCTGCTGGC	AGGCTGTGGA	CCCCCTGCGA	1620
AGGACAGTGG	AGAAGTACAG	CATGGAGCCG	GACCCAGCAG	GACGGGATAT	CTCCATCCGC	1680
CCTCTCCTGG	AGCACTGTGA	GAACACCCAT	ATGACCATCT	GGCTTGGCAT	CGTCTATGCC	1740
TACAAGGGAC	TTCTCATGTT	GTTGCGTTGT	TTCTTAGCTT	GGGAGACCCG	CAACGTCAGC	1800
ATCCCTGCAC	TCAACGACAG	CAAGTACATC	GGGATGAGTG	TCTACAACGT	GGGGATCATG	1860
TGCATCATCG	GGGCCGCTGT	CTCCTTCCTG	ACCCGGGACC	AGCCCAATGT	GCAGTTCTGC	1920
ATCGTGGCTC	TGGTCATCAT	CTTCTGCAGC	ACCATCACCC	TCTGCCTGGT	ATTCTGTGCC	1980
AAGCTCATCA	CCCTGAGAAC	AAACCCAGAT	GCAGCAACGC	AGAACAGGCG	ATTCCAGTTC	2040
ACTCAGAATC	AGAAGAAAGA	AGATTCTAAA	ACGTCCACCT	CGGTCACCAG	TGTGAACCAA	2100
GCCAGCACAT	CCCGCCTGGA	GGGCCTACAG	TCAGAAAACC	ATCGCCTGCG	AATGAAGATC	2160
ACAGAGCTGG	ATAAAGACTT	GGAAGAGGTC	ACCATGCAGC	TGCAGGACAC	ACCAGAAAAG	2220
ACCACCTACA	TTAAACAGAA	CCACTACCAA	GAGCTCAATG	ACATCCTCAA	CCTGGGAAAC	2280
TTCACTGAGA	GCACAGATGG	AGGAAAGGCC	ATTTTAAAAA	ATCACCTTGA	TCAAAATCCC	2340
CAGCTACAGT	GGAACACAAC	AGAGCCCTCT	CGAACATGCA	AAGATCCTAT	AGAAGATATA	2400
AACTCTCCAG	AACACATCCA	GCGTCGGCTG	TCCCTCCAGC	TCCCCATCCT	CCACCACGCC	2460

3/7

```

TACCTCCCAT CCATCGGAGG CGTGGACGCC AGCTGTGTCA GCCCCTGCGT CAGCCCCACC 2520
GCCAGCCCCC GCCACAGACA TGTGCCACCC TCCTTCCGAG TCATGGTCTC GGGCCTGTAA 2580
GGGTGGGAGG CCTGGGCCCC GGGCCTCCCC CGTGACAGAA CCACACTGGG CAGAGGGGTC 2640
TGCTGCAGAA ACACTGTCGG CTCTGGCTGC GGAGAAGCTG GGCACCATGG CTGGCCTCTC 2700
AGGACCACTC GGATGGCACT CAGGTGGACA GGACGGGGCA GGGGGAGACT TGGCACCTGA 2760
CCTCGAGCCT TATTTGTGAA GTCCTTATTT CTTCAAAAG AAGAGGAACG GAAATGGGAC 2820
GTCTTCCTTA ACATCTGCAA ACAAGGAGGC GCTGGGATAT CAAACTTGCA AAAAAAAAAA 2880
AAAAAAA

```

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 859 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```

Met Pro Pro Pro Pro Ala Arg Leu Leu Leu Leu Leu Leu Pro Leu
 1          5          10          15
Leu Leu Pro Leu Ala Pro Gly Ala Trp Gly Trp Ala Arg Gly Ala Pro
 20          25          30
Arg Pro Pro Pro Ser Ser Pro Pro Leu Ser Ile Met Gly Leu Met Pro
 35          40          45
Leu Thr Lys Glu Val Ala Lys Gly Ser Ile Gly Arg Gly Val Leu Pro
 50          55          60
Ala Val Glu Leu Ala Ile Glu Gln Ile Arg Asn Glu Ser Leu Leu Arg
 65          70          75          80
Pro Tyr Phe Leu Asp Leu Arg Leu Tyr Asp Thr Glu Cys Asp Asn Ala
 85          90          95
Lys Gly Leu Lys Ala Phe Tyr Asp Ala Ile Lys Tyr Gly Pro Asn His
100          105          110
Leu Met Val Phe Gly Gly Val Cys Pro Ser Val Thr Ser Ile Ile Ala
115          120          125
Glu Ser Leu Gln Gly Trp Asn Leu Val Gln Leu Ser Phe Ala Ala Thr
130          135          140
Thr Pro Val Leu Ala Asp Lys Lys Lys Tyr Pro Tyr Phe Phe Arg Thr
145          150          155          160
Val Pro Ser Asp Asn Ala Val Asn Pro Ala Ile Leu Lys Leu Leu Lys
165          170          175
His Tyr Gln Trp Lys Arg Val Gly Thr Leu Thr Gln Asp Val Gln Arg
180          185          190
Phe Ser Glu Val Arg Asn Asp Leu Thr Gly Val Leu Tyr Gly Glu Asp
195          200          205
Ile Glu Ile Ser Asp Thr Glu Ser Phe Ser Asn Asp Pro Cys Thr Ser
210          215          220
Val Lys Lys Leu Lys Gly Asn Asp Val Arg Ile Ile Leu Gly Gln Phe
225          230          235          240
Asp Gln Asn Met Ala Ala Lys Val Phe Cys Cys Thr Pro Gln Gln Tyr
245          250          255

```

4/7

Glu Arg Glu Tyr Asn Asn Lys Arg Ser Gly Val Gly Pro Ser Lys Phe  
                   260                  265                  270  
 His Gly Tyr Ala Tyr Asp Gly Ile Trp Val Ile Ala Lys Thr Leu Gln  
                   275                  280                  285  
 Arg Ala Met Glu Thr Leu His Ala Ser Ser Arg His Gln Arg Ile Gln  
                   290                  295                  300  
 Asp Phe Asn Tyr Thr Asp His Thr Leu Gly Arg Ile Ile Leu Asn Ala  
 305                  310                  315                  320  
 Met Asn Glu Thr Asn Phe Phe Gly Val Thr Gly Gln Val Val Phe Arg  
                   325                  330                  335  
  
 Asn Gly Glu Arg Met Gly Thr Ile Lys Phe Thr Gln Phe Gln Asp Ser  
                   340                  345                  350  
 Arg Glu Val Lys Val Gly Glu Tyr Asn Ala Val Ala Asp Thr Leu Glu  
                   355                  360                  365  
 Ile Ile Asn Asp Thr Ile Arg Phe Gln Gly Ser Glu Pro Pro Lys Asp  
                   370                  375                  380  
 Lys Thr Ile Ile Leu Glu Gln Leu Arg Lys Ile Ser Leu Pro Leu Tyr  
 385                  390                  395                  400  
 Ser Ile Leu Ser Ala Leu Thr Ile Leu Gly Met Ile Met Ala Ser Ala  
                   405                  410                  415  
 Phe Leu Phe Phe Asn Ile Lys Asn Arg Asn Gln Lys Leu Ile Lys Met  
                   420                  425                  430  
 Ser Ser Pro Tyr Met Asn Asn Leu Ile Ile Leu Gly Gly Met Leu Ser  
                   435                  440                  445  
 Tyr Ala Ser Ile Phe Leu Phe Gly Leu Asp Gly Ser Phe Val Ser Glu  
                   450                  455                  460  
 Lys Thr Phe Glu Thr Leu Cys Thr Val Arg Thr Trp Ile Leu Thr Val  
 465                  470                  475                  480  
 Gly Tyr Thr Thr Ala Phe Gly Ala Met Phe Ala Lys Thr Trp Arg Val  
                   485                  490                  495  
 His Ala Ile Phe Lys Asn Val Lys Met Lys Lys Lys Ile Ile Lys Asp  
                   500                  505                  510  
 Gln Lys Leu Leu Val Ile Val Gly Gly Met Leu Leu Ile Asp Leu Cys  
                   515                  520                  525  
 Ile Leu Ile Cys Trp Gln Ala Val Asp Pro Leu Arg Arg Thr Val Glu  
                   530                  535                  540  
 Lys Tyr Ser Met Glu Pro Asp Pro Ala Gly Arg Asp Ile Ser Ile Arg  
 545                  550                  555                  560  
 Pro Leu Leu Glu His Cys Glu Asn Thr His Met Thr Ile Trp Leu Gly  
                   565                  570                  575  
 Ile Val Tyr Ala Tyr Lys Gly Leu Leu Met Leu Phe Gly Cys Phe Leu  
                   580                  585                  590  
 Ala Trp Glu Thr Arg Asn Val Ser Ile Pro Ala Leu Asn Asp Ser Lys  
                   595                  600                  605  
 Tyr Ile Gly Met Ser Val Tyr Asn Val Gly Ile Met Cys Ile Ile Gly  
                   610                  615                  620  
 Ala Ala Val Ser Phe Leu Thr Arg Asp Gln Pro Asn Val Gln Phe Cys  
 625                  630                  635                  640  
 Ile Val Ala Leu Val Ile Ile Phe Cys Ser Thr Ile Thr Leu Cys Leu  
                   645                  650                  655  
 Val Phe Val Pro Lys Leu Ile Thr Leu Arg Thr Asn Pro Asp Ala Ala  
                   660                  665                  670  
 Thr Gln Asn Arg Arg Phe Gln Phe Thr Gln Asn Gln Lys Lys Glu Asp  
                   675                  680                  685  
 Ser Lys Thr Ser Thr Ser Val Thr Ser Val Asn Gln Ala Ser Thr Ser  
                   690                  695                  700  
 Arg Leu Glu Gly Leu Gln Ser Glu Asn His Arg Leu Arg Met Lys Ile  
 705                  710                  715                  720

5/7

```

Thr Glu Leu Asp Lys Asp Leu Glu Glu Val Thr Met Gln Leu Gln Asp
              725                      730                      735
Thr Pro Glu Lys Thr Thr Tyr Ile Lys Gln Asn His Tyr Gln Glu Leu
              740                      745                      750
Asn Asp Ile Leu Asn Leu Gly Asn Phe Thr Glu Ser Thr Asp Gly Gly
              755                      760                      765
Lys Ala Ile Leu Lys Asn His Leu Asp Gln Asn Pro Gln Leu Gln Trp
              770                      775                      780

Asn Thr Thr Glu Pro Ser Arg Thr Cys Lys Asp Pro Ile Glu Asp Ile
785                      790                      795                      800
Asn Ser Pro Glu His Ile Gln Arg Arg Leu Ser Leu Gln Leu Pro Ile
              805                      810                      815
Leu His His Ala Tyr Leu Pro Ser Ile Gly Gly Val Asp Ala Ser Cys
              820                      825                      830
Val Ser Pro Cys Val Ser Pro Thr Ala Ser Pro Arg His Arg His Val
              835                      840                      845
Pro Pro Ser Phe Arg Val Met Val Ser Gly Leu
              850                      855

```

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1318 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

GGCACGAGGA TCATTCGGGG CTGGTACGAG CCTTCTTGGT GGGAGCAGGT GCACACGGAA      60
GCCAACTCAT CCCGCTGCCT CCGGAAGAAT CTGCTTGCTG CCATGGAGGG CTACATTGGC      120
GTGGATTTCG AGCCCCTGAG CTCCAAGCAG ATCAAGACCA TCTCAGGAAA GACTCCACAG      180
CAGTATGAGA GAGAGTACAA CAACAAGCGG TCAGGCGTGG GGCCAGCAA GTTCCACGGG      240
TACGCCTACG ATGGCATCTG GGTCAATCGC AAGACACTGC AGAGGGCCAT GGAGACACTG      300
CATGCCAGCA GCCGGCACCA GCGGATCCAG GACTTCAACT ACACGGACCA CACGCTGGGC      360
AGGATCATCC TCAATGCCAT GAACGAGACC AACTTCTTCG GGGTCACGGG TCAAGTTGTA      420
TTCCGGAATG GGGAGAGAAT GGGGACCATT AAATTTACTC AATTTCAAGA CAGCAGGGAG      480
GTGAAGGTGG GAGAGTACAA CGCTGTGGCC GACACACTGG AGATCATCAA TGACACCATC      540
AGGTTCCAAG GATCCGAACC ACCAAAAGAC AAGACCATCA TCCTGGAGCA GCTGCGGAAG      600
ATCTCCCTAC CTCTCTACAG CATCCTCTCT GCCCTCACCA TCCTCGGGAT GATCATGGCC      660
AGTGCTTTTC TCTTCTTCAA CATCAAGAAC CGGAATCAGA AGCTCATAAA GATGTCGAGT      720
CCATACATGA ACAACCTTAT CATCCTTGGA GGGATGCTCT CCTATGCTTC CATATTTCTC      780
TTTGGCCTTG ATGGATCCTT TGTCTCTGAA AAGACCTTTG AAACACTTTG CACCGTCAGG      840
ACCTGGATTC TCACCGTGGG CTACACGACC GCTTTTGGGG CCATGTTTGC AAAGACCTGG      900
AGAGTCCACG CCATCTTCAA AAATGTGAAA ATGAAGAAGA AGATCATCAA GGACCAGAAA      960

```

6/7

CTGCTTGTGA	TCGTGGGGGG	CATGCTGCTG	ATCGACCTGT	GTATCCTGAT	CTGCTGGCAG	1020
GCTGTGGACC	CCCTGCGAAG	GACAGTGGAG	AAGTACAGCA	TGGAGCCGGA	CCCAGCAGGA	1080
CGGGATATCT	CCATCCGCCC	TCTCCTGGAG	CACTGTGAGA	ACACCCATAT	GACCATCTGG	1140
CTTGGCATCG	TCTATGCCTA	CAAGGGACTT	CTCATGTTGT	TCGGTTGTTT	CTTAGCTTGG	1200
GAGACCCGCA	ACGTCAGCAT	CCCCGCACTC	AACGACAGCA	AGTACATCGG	GATGAGTGTC	1260
TACAACGTGG	GGATCATCTC	GTGCCGAATT	CGATATCAAG	CTTATCGATA	CCGTCGAC	1318

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 332 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Arg	Ile	Gln	Asp	Phe	Asn	Tyr	Thr	Asp	His	Thr	Leu	Gly	Arg	Ile	Ile	1	5	10	15
Leu	Asn	Ala	Met	Asn	Glu	Thr	Asn	Phe	Phe	Gly	Val	Thr	Gly	Gln	Val	20	25	30	
Val	Phe	Arg	Asn	Gly	Glu	Arg	Met	Gly	Thr	Ile	Lys	Phe	Thr	Gln	Phe	35	40	45	
Gln	Asp	Ser	Arg	Glu	Val	Lys	Val	Gly	Glu	Tyr	Asn	Ala	Val	Ala	Asp	50	55	60	
Thr	Leu	Glu	Ile	Ile	Asn	Asp	Thr	Ile	Arg	Phe	Gln	Gly	Ser	Glu	Pro	65	70	75	80
Pro	Lys	Asp	Lys	Thr	Ile	Ile	Leu	Glu	Gln	Leu	Arg	Lys	Ile	Ser	Leu	85	90	95	
Pro	Leu	Tyr	Ser	Ile	Leu	Ser	Ala	Leu	Thr	Ile	Leu	Gly	Met	Ile	Met	100	105	110	
Ala	Ser	Ala	Phe	Leu	Phe	Phe	Asn	Ile	Lys	Asn	Arg	Asn	Gln	Lys	Leu	115	120	125	
Ile	Lys	Met	Ser	Ser	Pro	Tyr	Met	Asn	Asn	Leu	Ile	Ile	Leu	Gly	Gly	130	135	140	
Met	Leu	Ser	Tyr	Ala	Ser	Ile	Phe	Leu	Phe	Gly	Leu	Asp	Gly	Ser	Phe	145	150	155	160
Val	Ser	Glu	Lys	Thr	Phe	Glu	Thr	Leu	Cys	Thr	Val	Arg	Thr	Trp	Ile	165	170	175	
Leu	Thr	Val	Gly	Tyr	Thr	Thr	Ala	Phe	Gly	Ala	Met	Phe	Ala	Lys	Thr	180	185	190	
Trp	Arg	Val	His	Ala	Ile	Phe	Lys	Asn	Val	Lys	Met	Lys	Lys	Lys	Ile	195	200	205	
Ile	Lys	Asp	Gln	Lys	Leu	Leu	Val	Ile	Val	Gly	Gly	Met	Leu	Leu	Ile	210	215	220	
Asp	Leu	Cys	Ile	Leu	Ile	Cys	Trp	Gln	Ala	Val	Asp	Pro	Leu	Arg	Arg	225	230	235	240
Thr	Val	Glu	Lys	Tyr	Ser	Met	Glu	Pro	Asp	Pro	Ala	Gly	Arg	Asp	Ile	245	250	255	
Ser	Ile	Arg	Pro	Leu	Leu	Glu	His	Cys	Glu	Asn	Thr	His	Met	Thr	Ile	260	265	270	

7/7

Trp	Leu	Gly	Ile	Val	Tyr	Ala	Tyr	Lys	Gly	Leu	Leu	Met	Leu	Phe	Gly
	275						280					285			
Cys	Phe	Leu	Ala	Trp	Glu	Thr	Arg	Asn	Val	Ser	Ile	Pro	Ala	Leu	Asn
	290						295				300				
Asp	Ser	Lys	Tyr	Ile	Gly	Met	Ser	Val	Tyr	Asn	Val	Gly	Ile	Ile	Ser
305					310					315					320
Cys	Arg	Ile	Arg	Tyr	Gln	Ala	Tyr	Arg	Tyr	Arg	Arg				
				325					330						